Hirschsprung disease (HD) is a congenital malformation resulting from the lack of migration of ganglion cells in the colon. The absence of ganglion cells in rectal suction biopsies aids in diagnosis, but evaluation of these small biopsies can be difficult. In this study, we compare the microtubule-associated protein-2 (MAP-2), calretinin, and peripherin immunohistochemical stains in 237 selected biopsies performed to rule out HD. By H&E stain, a total of 78 biopsies had ganglion cells, whereas 83 biopsies had no ganglion cells, and an additional 76 biopsies were equivocal for ganglion cells. Of the 78 biopsies with ganglion cells, MAP-2 was positive in 73 (94%), calretinin in 76 (97%), and peripherin in 78 (100%). Of the 83 biopsies with no ganglion cells, calretinin and peripherin highlighted nerve fibrils and ganglion cells, respectively, in 3 biopsies, whereas MAP-2 was positive in only 1 biopsy. Of the 76 biopsies equivocal for ganglion cells, 16 cases were positive by all 3 stains, an additional case by both calretinin and peripherin, and 2 cases by peripherin only. All of the newly positive biopsies were from patients without HD. This study demonstrates that peripherin is superior in helping to rule out HD in these small biopsies, highlighting ganglion cells in virtually all cases with ganglion cells, whereas MAP-2 and calretinin are less sensitive for identification of ganglion cells and nerve fibrils, respectively. In patients with HD, a panel using calretinin and peripherin with or without MAP-2 may be most helpful in identifying transition zones.
H irschsprung disease (HD), also known as congenital intestinal aganglionosis, is a malformation of the enteric nervous system in which ganglion cells fail to migrate the entire length of the colon. The disease affects approximately 1 in 5000 liveborn infants. Multiple genes have been linked to HD, some of which are associated with isolated disease, whereas others are associated with syndromes which include colonic aganglionosis (reviewed in Kapur 1 ) . While most individuals present in infancy with an inability to pass meconium or constipation with abdominal distention, presentations later in life can occur with symptoms of chronic constipation or enterocolitis. 2 The diagnosis is suggested by these clinical features and radiology, but the gold standard for diagnosis is made by rectal suction biopsy. 1 These suction biopsies should contain both mucosa and submucosa. By histology, the diagnosis is confirmed by a lack of ganglion cells in the submucosal nerve plexuses and neural hypertrophy. Neural hypertrophy at a measurement of >40 mm has been strongly correlated with HD. 3 The pathologist's role in the diagnosis is to evaluate the colon/rectal biopsy for ganglion cells and neural hypertrophy. However, many difficulties arise in this process. The biopsy should include both mucosa and submucosa, but many times the biopsies are too superficial for evaluation of the submucosa, where the ganglion cells reside. Rates of insufficient/inadequate biopsies due to lack of submucosa have been reported between 10% and 20%, and as high as 24%. 4, 5 In addition, even in normal individuals, there is a physiological hypoganglionic zone that is proximal to the pectinate line, which may lead to overdiagnosis of HD due to a lack of, or decrease in, ganglion cells. Lastly, in newborns and infants, immature ganglion cells lacking abundant cytoplasm are often present, which can morphologically be confused with endothelial cells, fibroblasts, or inflammatory cells, hampering diagnosis by pathologists who do not regularly read these biopsies.
Many institutions, especially academic pediatric hospitals, evaluate serial hematoxylin and eosin (H&E) section levels to identify ganglion cells, with sometimes >100 sections reviewed. 6 Other institutions may view less H&E levels and use histochemical and/or immunohistochemical stains to aid in the diagnosis. Throughout the years, many different stains have been utilized to help evaluate for HD. More recently, calretinin immunohistochemistry has come into favor as it identifies the small neurites in the muscularis mucosa and lamina propria in normal colon biopsies which are absent by stain in HD biopsies. 7 An underutilized stain for evaluation of HD is peripherin, a type III intermediate filament protein, and a specific marker for the peripheral nervous system neurons. 8, 9 In 1996, Szabolcs et al 10 identified peripherin to label both immature and mature ganglion cells in biopsies for HD. Peripherin also highlighted more ganglion cells than other neural markers including neurofilament, neuron-specific enolase (NSE), and S100. More recently, peripherin was detailed to be part of a highly sensitive and specific protocol for identification of ganglion cells to rule out HD at the Medical College of Georgia. 11 In a recent study, 12 we examined the microtubuleassociated protein-2 (MAP-2) antibody in approximately 250 biopsies sent to pathology for the evaluation of HD. MAP-2 was highly sensitive and specific for identifying ganglion cells, and aided in evaluation of many biopsies that were originally negative or equivocal for ganglion cells by H&E. In this study, we now compare the performance of MAP-2, calretinin, and peripherin antibodies to help determine if any or all of the stains are helpful in the evaluation for HD.
MATERIALS AND METHODS
Rectal and colon biopsies performed to evaluate for HD were identified as previously reported by Burtelow and Longacre. 12 In brief, the Stanford pathology database was searched for biopsies performed to rule out HD between January 1999 and June 2008. During this time period, all biopsies submitted were embedded and serially sectioned through exhaustion of the formalin-fixed paraffin-embedded (FFPE) tissue in a total of Z20 slides with 3 to 5 sections per slide for H&E staining. The slides from each of the identified cases were retrieved and reviewed for the presence of ganglion cells. While numerous more biopsies performed to rule out HD were identified in the database, only 237 biopsies were selected, representing 131 cases/112 patients, with a median age of 5 weeks, and range of 1 day to 16 years. These biopsies represented approximately equal numbers of cases where ganglion cells were identified (78 biopsies from 53 cases/53 patients), absent (83 biopsies from 41 cases/38 patients), or equivocal (76 biopsies from 53 cases/48 patients). Due to some patients having multiple biopsies, a single patient may have had a biopsy where ganglion cells were identified as well as a biopsy which was equivocal for ganglion cells. Overall, of the 112 patients, 34 had a diagnosis of HD (median age 9 d; range, 2 d to 3 y), and 78 did not have a diagnosis of HD (median age 3 mo; range, 1 d to 16 y). Diagnoses of HD were based upon the biopsies used for this study, repeat biopsies, and/or pullthrough resections. Three patients did not have clinical or pathologic follow-up; however, in performing this study, their biopsies, originally found to be equivocal based upon H&E staining, were positive by all 3 stains. As such, these patients were considered to have normal ganglionosis and not have HD.
Due to exhaustion of the FFPE tissue at the time of diagnosis, 3 sequential slides from each of the original H&E series were decoverslipped and destained as previously described. 12 Immunohistochemistry was performed using a mouse monoclonal anti-peripherin antibody (LS-B6138; LifeSpan BioSciences Inc., Seattle, WA). At a 1:400 dilution, peripherin was stained using the VECTASTAIN Elite ABC Kit (PK6102; Vector Laboratories Inc., Burlingame, CA). For MAP-2 (MAB3418; Millipore, Billerica, MA), automated staining was performed using the Leica BOND-MAX instrument (Leica Biosystems, Buffalo Grove, IL), at a 1:3000 dilution with Leica's proprietary antigen retrieval solution, pH 6.0. Immunohistochemical staining for calretinin (232A-76; Cell Marque Corporation, Rocklin, CA) was performed at a 1:200 dilution using Ventana's proprietary antigen retrieval solution, pH 8.5 (Ventana Medical Systems Inc., Tucson, AZ). All stains were visualized using diaminobenzidine (DAB) as the chromogen (Dako, Carpinteria, CA). Stains were scored as positive, equivocal, or negative by both authors. If any stains trios were discrepant in a biopsy, the stains were repeated on the next consecutive slide to confirm the findings. The cases in which there was too little or no submucosa, faint staining, or nonspecific staining were termed equivocal.
All of the previously performed MAP-2 stains 12 were reviewed and rescored as positive, negative, and equivocal. Due to the inability to find enough slides to destain, unknown outcomes, and reclassification of some cases from negative to equivocal for ganglion cells, the total numbers of cases were different between papers: the cases with absent ganglion cells or equivocal for ganglion cells went from 91 to 83, and 78 to 76, respectively. Two of these reclassified cases were positive for MAP-2. Of note, for all biopsies in which the MAP-2-stained slide was reclassified from positive to negative or equivocal, most often due to the stain fading over time, an additional H&E slide was destained and restained for MAP-2 as detailed above.
Sensitivity and specificity values were calculated using 2 Â 2 contingency tables. The McNemar test was utilized to determine the statistical significance of differences between paired stains, with a 2-tailed P-value. Statistical analysis was performed using GraphPad Software (GraphPad Software Inc., La Jolla, CA).
RESULTS

Immunohistochemical Stains in Cases With Ganglion Cells Identified by H&E
Of the 237 selected biopsies, 78 biopsies had ganglion cells identified by H&E stain. These biopsies were taken from patients with a median age of 12 weeks (range, 1 d to 16 y) being evaluated for HD, including 74 biopsies taken from patients found to not have HD and 4 biopsies taken proximal to the involved HD segment. Immunohistochemical staining for MAP-2 specifically highlighted ganglion cells without labeling other neural elements, whereas immunohistochemical staining with calretinin highlighted lamina propria and mucosal neurites. Peripherin immunohistochemical staining strongly and solidly highlighted the cytoplasm of ganglion cells; the stain also highlighted neural elements in a band-like pattern. Table 1 , peripherin stained ganglion cells in all 78 (100%) of these biopsies, calretinin stained mucosal and lamina propria neurites in 76 (97%) of the biopsies, and MAP-2 highlighted ganglion cells in 73 (94%) of the biopsies. Figure 1 , row 1 demonstrates a case which was positive for all 3 of these stains. Of all 78 biopsies, 71 (91%) were positive by all 3 stains, whereas 7 biopsies were positive by only 1 or 2 stains. In the cases in which MAP-2 was negative, ganglion cells were identified in the biopsy, but were negative for staining; in addition, positive internal controls were identified on these slides. An example of a case with negative MAP-2 staining but with H&E evidence of ganglion cells is illustrated in row 2 of Figure 1 .
As shown in
Immunohistochemical Stains in Cases Without Ganglion Cells Identified by H&E
A total of 83 biopsies were selected that did not contain ganglion cells by H&E staining, including 77 biopsies from patients with HD and 6 patients without HD (median age 9 d; range, 2 d to 16 y). Of these 83 biopsies, calretinin highlighted mucosal and lamina propria neurites and peripherin highlighted ganglion cells in 3 biopsies (Table 1 ). In addition, MAP-2 was positive in one of these 3 cases. An example of one of the biopsies with calretinin and peripherin positivity is exhibited in row 3 of Figure 1 . These 3 newly positive biopsies were from patients without HD.
Immunohistochemical Stains in Cases Equivocal for Ganglion Cells by H&E
In this study, 76 biopsies were equivocal for ganglion cells on H&E step level sections, with 22 biopsies from patients found to have HD and 54 biopsies from patients found not to have HD (median age 6 wk; range, 1 d to 14 y). Of these biopsies, 28 lacked submucosa and/or were markedly fragmented, and thus were suboptimal/inadequate for evaluation; these cases included 10 cases found to represent HD and 18 cases without a diagnosis of HD. Calretinin, peripherin, and MAP-2 were not positive in any of these inadequate biopsies. The remaining 48 specimens consisted of biopsies with very little submucosa, of which 16 were positive by all 3 immunohistochemical stains ( Table 1 ). All of these 16 newly positive cases were from patients without HD. Furthermore, 1 additional case was positive by both calretinin and peripherin, and 2 additional cases were positive by only peripherin. These latter 3 cases were from patients without HD on follow-up. The 29 biopsies that were negative/remained equivocal for all 3 stains included 12 biopsies from patients confirmed to have HD and 17 patients without HD. Figure 1, row 4 illustrates one of the cases that was positive by only peripherin immunohistochemical staining.
Correlation Between Immunohistochemical Stains and H&E Evaluation
As depicted in Table 1 , the peripherin immunohistochemical stain identified ganglion cells in all cases in which ganglion cells were present by H&E, and also identified ganglion cells in all cases that were negative or equivocal for ganglion cells by H&E but positive by calretinin and/or MAP-2 immunohistochemical stains, for a total of 100 positive cases. In addition, peripherin was negative in 80 cases (cases with absent ganglion cells by H&E stain and negative by peripherin staining). Thus, using peripherin immunohistochemical staining as the reference standard for this study, H&E staining had a sensitivity of 78%. By the McNemar test, peripherin staining was significantly better than H&E staining (P < 0.0001). When correlating peripherin and calretinin immunohistochemical stains, calretinin had a sensitivity of 96% and a specificity of 100% compared with peripherin; by the McNemar test, there was no statistical significance between these 2 stains (P = 0.1336). Lastly, when comparing peripherin and MAP-2 immunohistochemical stains, MAP-2 had a sensitivity of 90% and a specificity of 100%. Compared with MAP-2, peripherin was significantly better in this series by the McNemar test (P = 0.0044).
DISCUSSION
In this study, we used 3 immunohistochemical stains to help evaluate rectal suction biopsies for HD. While MAP-2 specifically and only highlighted ganglion cells, calretinin highlighted small mucosal and lamina propria nerve fibrils, and peripherin differentially highlighted all neural elements. Peripherin strongly labeled the cytoplasm of ganglion cells, and also stained other neural elements in a band-like pattern. This staining pattern for peripherin is consistent with previous reports; Holland et al 11 showed that peripherin robustly stained the cytoplasm of ganglion cells, and also demonstrated a weak linear granular staining of nerve fibers. We agree with these authors that differentiating the staining patterns to definitively identify the ganglion cells is not difficult. Over the years, numerous techniques have been evaluated to identify the most sensitive, specific, and costeffective method to assist in a timely diagnosis of HD. One of the first histochemical stains to be evaluated which is still used to this day was acetylcholinesterase. 13 Unlike most stains, acetylcholinesterase is positive in HD and negative in normal colon, highlighting the thickened nerve fibers in the muscularis mucosa and lamina propria in diseased patients with increased enzyme activity. However, this stain requires frozen tissue and specialized laboratory personnel. Immunohistochemical stains on FFPE tissue, such as S-100, GLUT-1, and NSE have also been used to help identify nerve proliferations, 11, [14] [15] [16] whereas stains such as NSE, anti-ret, anti-NeuN, and MAP-2 have been used to highlight ganglion cells. 12, 14, [17] [18] [19] In recent years, calretinin immunohistochemistry has become highly utilized among pathologists due to its ability to highlight the small lamina propria and mucosal nerve fibers that would not be apparent by H&E; these neuritis are absent in HD. 7 This marker is also of potential use in identifying the transition zone in patients with known HD. Some studies have shown that calretinin is more accurate than acetylcholinesterase staining, is easier to perform and interpret, and improves diagnostic accuracy in HD. [20] [21] [22] [23] [24] In this current study, calretinin was statistically equivalent to peripherin in its ability to help exclude HD. FIGURE 1. Rectum suction biopsy low-power H&E sections with associated higher power immunohistochemical staining. The first row demonstrates a rectal biopsy with H&E findings of identified ganglion cells (inset). MAP-2, calretinin, and peripherin stains are all positive in this biopsy for ganglion cells (MAP-2 and peripherin) and mucosal and lamina propria nerve fibrils (calretinin). The second row demonstrates an H&E with identified ganglion cells (inset). Both calretinin and peripherin stains are positive, but MAP-2 does not highlight the identified ganglion cells in this biopsy. The third row shows a rectal biopsy with no ganglion cells identified on H&E, but with lamina propria nerve fibers identified on calretinin stain and ganglion cells identified on peripherin stain. MAP-2 staining is negative in this biopsy. The fourth row shows an H&E biopsy that is equivocal for ganglion cells; MAP-2 staining for ganglion cells is equivocal as is the calretinin stain for mucosal and lamina propria nerve fibrils, but peripherin staining identifies ganglion cells. H&E at 10 Â . H&E indicates hematoxylin and eosin; MAP-2, microtubule-associated protein-2.
Compared with MAP-2, peripherin staining in the current study was more sensitive in identifying ganglion cells. Other studies have similarly shown that peripherin more successfully identifies ganglion cells when compared with neurofilament, NSE, S-100, cathepsin D, PGP 9.5, synaptophysin, and chromogranin immunohistochemical stains. 10, 25 Also of note, in this study peripherin appears to quantitatively stain more ganglion cells than MAP-2 (data not shown). Moreover, as reported by Szabolcs et al, 10 peripherin highlights not only the mature ganglion cells but also the immature ganglion cells with equal intensity. These immature ganglion cells are more common in neonates, who comprise the majority of the population in whom biopsies are taken to rule out HD.
One disadvantage of this study was the need to destain H&E slides to perform the immunohistochemistry. As this was a retrospective study, we were limited by our previous Hirschsprung protocol, which consisted of serially sectioning through and exhausting the FFPE tissue for H&E slide staining. We believe that many of our equivocal H&E cases that remained equivocal after immunohistochemical staining may have been resolved had our tissue not required destaining and restaining. Many of our calretinin slides had very faint staining that was difficult to evaluate as true staining versus nonspecific staining; in addition, many stained slides were negative for immunohistochemistry without internal controls. The destaining and restaining process has been previously reported to result in suboptimal staining. In their report of destaining and restaining 105 prostate needle biopsies with high-molecular-weight cytokeratin, Dardik and Epstein 26 found that tissue fell off the slide in 9% of cases, the stain did not work in 19% of cases, and the stain was suboptimal in 21% of cases. Ideally, a prospective study incorporating each of these stains should be undertaken to determine a more accurate sensitivity, specificity, and comparison between H&E, peripherin, calretinin, and MAP-2 staining.
To compound our destaining disadvantage, another limitation of this study was the use of previously stained MAP-2 slides from a study performed 5 years prior which also used the same H&E destaining technique. While many of these MAP-2-stained slides had faded over time, we tried to correct for this potential problem by repeating the stain on a freshly destained H&E slide in every case that we had reclassified from positive to negative or equivocal. In total, we repeated the MAP-2 staining on 17 biopsies (7% of all cases), of which 10 cases were scored similarly to our reviewed slide and 7 cases were found to be positive.
Lastly, our inclusion of a large quantity of equivocal biopsies by H&E, most due to lack of, or limited, submucosa could be considered a weakness of our study. However, this study aimed to investigate approximately equal numbers of equivocal biopsies to those with and without ganglion cells identified. Another reason for this large quantity of equivocal cases was to attempt to use the immunohistochemical stains to enhance the histologic diagnosis of the biopsies (from equivocal for ganglion cells to positive for ganglion cells). Indeed, the diagnoses of 19 of these biopsies were improved by the use of immunohistochemical stains which identified ganglion cells and/or mucosal and lamina propria neurites. However, even after the immunohistochemical stains, 29 of the cases that contained at least some submucosa remained equivocal. Although 12 of these 29 cases were confirmed on follow-up to represent HD, the remaining 17 cases did not have a diagnosis of HD. As previously discussed, some of these cases may have remained equivocal due to destaining and restaining. These 17 cases that remained equivocal with lack of peripherin and MAP-2 ganglion cell staining could be called falsely negative. To account for this increased number of cases that remained equivocal or suboptimal for diagnosis, when comparing the immunohistochemical and H&E stains, we only included the biopsies that were definitively positive or negative by the stain, and not the 29 cases with submucosa or 28 cases without submucosa that remained equivocal/suboptimal.
Holland et al 11, 23 described a highly sensitive and specific protocol developed by the Medical College of Georgia for staining biopsies to rule out HD; this protocol included an initial 8 levels of H&E-stained slides with peripherin staining on 2 to 3 of the levels. If this evaluation was negative or equivocal, they then performed more H&E stains, as well as additional staining for peripherin, calretinin, and S-100. We agree with this stepwise approach. The current protocol at our institution is to initially cut 20 slides, each with 3 to 5 levels of biopsies, and perform H&E staining on alternate slides. If ganglion cells are not identified on the initial H&E series, immunohistochemical stains are performed on selected alternative levels and more slides are cut for H&E staining. On the basis of our current study, we would recommend immunohistochemical staining for at least peripherin and calretinin, which were statistically similar in identifying ganglion cells and nerve fibrils in the lamina propria, respectively, to help to rule out HD.
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